deltatrials
Completed PHASE1/PHASE2 NCT00139243

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

A Phase I/II Study of Taxotere, Cisplatin, 5-Fluorouracil and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

Sponsor: Beth Israel Deaconess Medical Center

Conditions Carcinoma of Head and/or Neck Squamous Cell Carcinoma
Interventions 5-Fluorouracil Cisplatin Leucovorin Taxotere
Updated 5 times since 2017 Last updated: Jun 2, 2008 Started: Oct 31, 1997 Primary completion: Jan 31, 2006 Completion: Jan 31, 2006

A PHASE1/PHASE2 clinical study on Carcinoma of Head and/or Neck and Squamous Cell Carcinoma, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 5 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
  • Sanofi
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States